BioHealthonomics
Early Stage
BioHealthonomics is a pharmaceutical company developing a proprietary, industry unique technology for the treatment and prevention of migraine headaches.
Overview
Raised: $36,600
Rolling Commitments ($USD)
Status
Funded
Reporting Date
02/28/2018
Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise
$407
# of Investors
78
Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded
2011
Industry
Healthcare & Pharmaceuticals
Tech Sector
Location
Santa Monica, California
The throbbing. The nausea. The flickering lights, neck pains, and feeling like it will never end. When you get a migraine, life seems to stop.
BioHealthonomics is here to help. They are a pharmaceutical company developing an industry unique technology for the treatment and prevention of migraine headaches. Their technology addresses the root cause of the problem by targeting the histamine receptors found to be involved in migraine headaches. People susceptible to migraines have a tendency to release excess histamine when introduced to a stressor or trigger, which is what causes the headache. BioHealthonomics’ treatment helps prevent that release of excess histamine from happening. Less histamine means less migraines -- and who doesn’t want that?
So far, clinical studies have found their treatment works in over 80% of migraine patients, versus the traditional migraine treatment of using CGRP antibodies, which only works in 50% of patients. BioHealthonomics believes their technology is superior to CGRP antibodies both in terms of safety efficacy and cost standpoints, and they have a clear path for continuing to develop an extremely effective, side effects free treatment.
So far, they have two issued patents in the U.S. and patents pending in five additional markets. They’ve also entered into a strategic agreement with another pharmaceutical company to gain access to pre-clinical, phase I clinical, and chemistry, manufacturing, and controls data. This will save millions of dollars in development costs, as well as years in development time.
Migraines are the sixth most disabling disorder in the U.S., with over 30 million people suffering from them. In fact, $50 billion is lost each year because of medical expenses caused by headaches, reduced employee productivity, and absenteeism. The migraine product market is currently $3.4 billion, with projections to grow up to $10 billion in the next decade, and BioHealthonomics, with their industry unique treatment, is poised to be the leader in this market.
You could truly be on your way to being headache free. BioHealthonomics has the technology to make that dream a reality. A life without migraines….just imagine all of the possibilities.
“Who Should Be Interested in this Offer:”
If you’re someone who suffers from migraines, or if someone close to you does, then BioHealthonomics is worth your attention. They are offering a solution that addresses the root of the problem and has proven to be more successful than current available treatments. If you want to say goodbye to migraines (and possibly profit at the same time!), then investing in BioHealthonomics might just be the headache-free choice for you.
BioHealthonomics is here to help. They are a pharmaceutical company developing an industry unique technology for the treatment and prevention of migraine headaches. Their technology addresses the root cause of the problem by targeting the histamine receptors found to be involved in migraine headaches. People susceptible to migraines have a tendency to release excess histamine when introduced to a stressor or trigger, which is what causes the headache. BioHealthonomics’ treatment helps prevent that release of excess histamine from happening. Less histamine means less migraines -- and who doesn’t want that?
So far, clinical studies have found their treatment works in over 80% of migraine patients, versus the traditional migraine treatment of using CGRP antibodies, which only works in 50% of patients. BioHealthonomics believes their technology is superior to CGRP antibodies both in terms of safety efficacy and cost standpoints, and they have a clear path for continuing to develop an extremely effective, side effects free treatment.
So far, they have two issued patents in the U.S. and patents pending in five additional markets. They’ve also entered into a strategic agreement with another pharmaceutical company to gain access to pre-clinical, phase I clinical, and chemistry, manufacturing, and controls data. This will save millions of dollars in development costs, as well as years in development time.
Migraines are the sixth most disabling disorder in the U.S., with over 30 million people suffering from them. In fact, $50 billion is lost each year because of medical expenses caused by headaches, reduced employee productivity, and absenteeism. The migraine product market is currently $3.4 billion, with projections to grow up to $10 billion in the next decade, and BioHealthonomics, with their industry unique treatment, is poised to be the leader in this market.
You could truly be on your way to being headache free. BioHealthonomics has the technology to make that dream a reality. A life without migraines….just imagine all of the possibilities.
“Who Should Be Interested in this Offer:”
If you’re someone who suffers from migraines, or if someone close to you does, then BioHealthonomics is worth your attention. They are offering a solution that addresses the root of the problem and has proven to be more successful than current available treatments. If you want to say goodbye to migraines (and possibly profit at the same time!), then investing in BioHealthonomics might just be the headache-free choice for you.
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.